Danish drug manufacturer Novo Nordisk has flags with flags, blockbuster diabetes manufacturer and weight loss treatment, while the company presents an annual report at Novo Nordisk on 5 February 2025 at Denmark’s Bagwerad, Denmark.
Mads Claus Rasmusen | AFP | Getty images
Novo nordisk A major legal victory, which banned large -scale pharmacies from selling or selling cheap, sells cheap, unpublished versions of the drug manufacturer’s blockbuster weight drug vegovi and diabetes treatment ozmpic.
A federal judge in Texas on Thursday on Thursday rejected a bid to compound pharmacies to make copies of ozapic and vegovi, while a legal challenge on those drug shortages. It came from a compounding trade group in response to a February case against the determination of the Food and Drug Administration that the component in those drugs, semaglutide, is no less in America now.
Patients were instigated for cheap copying people when ozmpic and vegi were in low supply in the last two years, because due to skyrocketing demand, or if they did not have insurance coverage for expensive treatment.
during FDA-declared shortagePharmacists can legally create mixed versions of brand-name drugs. Many telehealth companies, such as Snow and itsThey also offered those imitations. But drug manufacturers and some health experts have pushed back against practice as the FDA does not approve mixed drugs, which are custom-made copies prescribed by a doctor to meet the needs of a specific patient.
“We are delighted that the court has rejected the efforts of compounders to reduce the FDA’s data-based decisions that the lack of semaglutide has been solved, Steve Benz, Novo Nordisk’s corporate vice-president, legal and US general lawyer said in a statement.
He said, “The patient’s safety is a top priority for Novo Nordisk and we have taken widespread nationwide legal action to protect Americans from the health risks arising from illegitimate ‘semglutide’ drugs, he said, referring to more than 100 cases against pharmaceuties and other institutions in 32 states.
On Thursday, US District Judge Mark Pitman denied the bid of the Outsourcing Facility Association for an initial prohibition, which would have prevented the FDA from taking action against its members to make copies of semaglutide.
This decision enhances FDA’s previous determination that the lack of semaglutide in the US is over and means that FDA can now go immediately after so -called 503A pharmacies who are creating mixed versions of semaglutide according to individual recipe for a specific patient.
Those pharmacies are largely regulated by states rather than FDA.
Those pharmacies make mixed drugs according to individual prescriptions for a specific patient and are largely regulated by states instead of FDA.
The decision also means that the FDA may start targeting federally regulated 503B pharmacies after 22 May or with or without recipe. Agency works may include product recovery and warning letters to pharmacies.
The decision on Thursday follows another win for Novo Nordisk. Earlier this week, a separate federal judge in Texas ruled in favor of a drug manufacturer against the 503A pharmacy, Mediok Pharmacy, permanently stopping the business from selling marketing or compound semglutide.
Novo Nordisk and Ellie lily Compounding in the last two years is aggressively torn on pharmacies as they benefit from their weight loss and increasing popularity of diabetes.
Ellie Lily has gone through one Similar legal process With tirzepatide, the active ingredient in its weight loss drug zepbound and diabetes treatment in Mounjaro. The FDA announced the US deficiency of tricolor compared to last year, inspiring the same compounding trade group to sue the FDA on the drug.
In March, a federal judge denied the request of the compounding group for initial prohibitory orders on the enforcement of the FDA against its members to create copies of Maunzaro and Zipbound. The compounding group has appealed.
